Floatz logo

HM15211 (LONG-ACTING GLP-1/GIP/GLUCAGON TRIPLE AGONIST)

NASH - Nonalcoholic Steatohepatitis

Hanmi Pharmaceutical Company Limitedprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

130 Active assets in the NASH - Nonalcoholic Steatohepatitis cohort.

Asset / SponsorPhaseRating
Resmetirom
City University of New York
Phase 4BBB
Pentoxifylline
Al-Azhar University
Phase 4BBB
Semaglutide
Cascade Pharmaceuticals, Inc
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Firsocostat
Gilead Sciences
Phase 2BBB

View all 50 →

Same molecule, other indications

HM15211 (LONG-ACTING GLP-1/GIP/GLUCAGON TRIPLE AGONIST) is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
CC
Indicative ·
44 / 100
View asset →
obesity disorderDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →